In order to improve the quality of health services by ensuring the accessibility of safe, efficacious, quality, and affordable drugs in sufficient types and quantities, especially in the implementation of the National Health Insurance (JKN), a National Formulary (Fornas) was prepared. 

Fornas is a list of selected drugs needed and used as a reference for writing prescriptions in the implementation of health services in the implementation of health insurance programs stipulated through the Decree of the Minister of Health Number HK.01.07/MENKES/2197/2023 concerning the National Formulary.

Adjusting to the conditions and technological advances, where new drugs are found, as well as health technology that is more directed towards precision medicine, it is necessary to periodically review Fornas in order to keep up with developments in the world of medicine and pharmacy to improve therapeutic success.

In addition, through the Fornas review, it will be ensured that the list of drugs listed in Fornas can fulfill the needs of medicines for health services in all health facilities, both First Level Health Service Facilities (FPKTP) and Advanced Health Service Facilities (FPKTL).

In order to facilitate this, the Directorate General of Pharmaceutical and Medical Devices of the Indonesian Ministry of Health through the Directorate of Pharmaceutical Management and Services has held a “National Formulary Review Meeting” on 9 to 10 July 2024 in Jakarta by involving various related parties including professional organizations of doctors and specialists, the Food and Drug Agency, BKKBN, BPJS Health and related units in the Ministry of Health.

The meeting, which was officially opened by the Director General of Pharmaceuticals and Medical Devices, L. Rizka Andalucia, was the first in a series of Fornas review activities for 2024, the final result of which will be stipulated as a Fornas addendum by the Indonesian Minister of Health.

The 2024 Fornas review has been in process with the opening of drug proposals through the e-Fornas web, and proposals have been received from hospitals, professional organizations, health offices and government agencies.

The assessment of drug proposals and evaluation in Fornas will be conducted by the Fornas Team through a series of Review Discussion Meetings and Plenary Meetings.

“By conducting regular reviews, it is expected that the implementation of Fornas in health care facilities will provide a choice of drugs that are safe, efficacious, quality, affordable, and based on the latest scientific evidence,” said the Director General.

This effort aims to improve the rationality and accuracy of drug use, improve therapeutic success and to achieve the highest degree of public health.